Stereotactic radiotherapy in metastatic breast cancer
Related Experiment Video
Updated: Feb 7, 2026
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Published on: July 3, 2014
Marco Possanzini1, Carlo Greco2
1Radiotherapy Department, Fundação Champalimaud, Lisbon, Portugal; Breast Unit Fundação Champalimaud, Lisbon, Portugal; Radiotherapy Department, Businco Oncological Hospital, Cagliari, Italy.
Abstract:
The treatment of metastatic breast cancer is largely focused on systemic therapy. However, over the past decades, there has been growing interest in the use of metastasis-directed therapy in selected cases presenting with an oligometastatic phenotype, i.e. low disease burden with a more indolent biology. Identification of the oligometastatic breast cancer population has, so far, proven elusive. Stereotactic radiotherapy offers an effective, non-invasive approach to ablate metastatic disease both in the brain and in extra-cranial settings. The advent of advanced imaging techniques for target definition, along with the ability to achieve highly conformal dose deposition with steep dose fall-off, enable safe implementation of extreme hypofractionated and single fraction regimens with ablative intent. There is growing evidence that radiation-based treatments are more cost-effective when compared to other ablative modalities. This article provides preliminary evidence that metastasis-direct ablation, with advanced radiotherapy techniques, may play an important role in the management of metastatic breast cancer patients, potentially improving clinical outcomes with minimal toxicity. However, prospective randomized controlled trials are needed to further the understanding of the interaction between systemic therapy and ablative irradiation. Additionally, research in genomic and molecular profiling is needed to characterize metastatic breast cancer patients who will most likely benefit from such combined treatment approaches.
Insights
Metastasis-directed therapy using advanced stereotactic radiotherapy shows promise for oligometastatic breast cancer. This approach may improve outcomes with minimal toxicity, but further research is needed.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Metastatic breast cancer treatment primarily relies on systemic therapy.
- Oligometastatic breast cancer, characterized by low disease burden and indolent biology, is a growing area of interest for targeted therapies.
- Identifying the oligometastatic breast cancer population remains a challenge.
Purpose of the Study:
- To explore the role of metastasis-directed therapy in managing metastatic breast cancer.
- To present preliminary evidence for the efficacy and safety of advanced radiotherapy techniques in ablating metastatic disease.
- To highlight the potential of stereotactic radiotherapy in selected metastatic breast cancer cases.
Main Methods:
- Utilizing stereotactic radiotherapy, an advanced non-invasive technique for ablating metastatic lesions.
- Employing advanced imaging for precise target definition.
- Implementing highly conformal dose deposition with steep dose fall-off for safe hypofractionated and single-fraction regimens.
Main Results:
- Stereotactic radiotherapy offers an effective method for ablating both intracranial and extracranial metastatic disease.
- Advanced radiotherapy techniques enable safe implementation of ablative regimens with minimal toxicity.
- Radiation-based treatments demonstrate cost-effectiveness compared to other ablative modalities.
Conclusions:
- Metastasis-directed ablation with advanced radiotherapy techniques may significantly benefit selected metastatic breast cancer patients.
- Further prospective randomized controlled trials are essential to validate these findings and understand the interplay with systemic therapy.
- Genomic and molecular profiling research is crucial to identify patients most likely to benefit from combined treatment approaches.
More Related Videos
Related Concept Videos
02:18Cancer
02:12What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
02:59Cancer Prevention
Some...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...